Medico Remedies Ltd is Rated Hold

Understanding the Current Rating

The 'Hold' rating assigned to Medico Remedies Ltd indicates a neutral stance for investors, suggesting that the stock is expected to perform in line with the broader market or sector averages in the near term. This rating reflects a balanced view of the company’s strengths and challenges, based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Quality Assessment

As of 14 February 2026, Medico Remedies Ltd maintains a good quality grade. The company demonstrates high management efficiency, evidenced by a robust Return on Capital Employed (ROCE) of 15.04%. This metric highlights the firm’s ability to generate profits from its capital base effectively. Furthermore, the company’s debt servicing capability remains strong, with a low Debt to EBITDA ratio of 0.89 times, indicating manageable leverage and financial stability.

Operationally, Medico Remedies has reported positive results for four consecutive quarters, underscoring consistent profitability. The latest half-year Profit After Tax (PAT) stands at ₹5.44 crores, reflecting a healthy growth rate of 30.46%. Additionally, the half-year ROCE has improved to 20.65%, signalling enhanced capital utilisation efficiency. Profit Before Tax excluding other income (PBT less OI) for the latest quarter is ₹3.15 crores, growing at an impressive 52.17%. These figures collectively affirm the company’s solid operational foundation and management effectiveness.

Valuation Perspective

Currently, the valuation grade for Medico Remedies Ltd is assessed as fair. The stock trades at an Enterprise Value to Capital Employed (EV/CE) ratio of 5.2, which is considered reasonable within the Pharmaceuticals & Biotechnology sector. This valuation suggests that the stock is priced at a discount relative to its peers’ historical averages, offering a potentially attractive entry point for investors seeking value.

Despite the stock’s recent underperformance in price terms, with a one-year return of -30.89% as of 14 February 2026, the company’s profits have grown by 31.1% over the same period. This divergence between earnings growth and stock price performance is reflected in a Price/Earnings to Growth (PEG) ratio of 1.1, indicating that the stock’s valuation is broadly aligned with its earnings growth prospects. Investors should note that the fair valuation grade implies limited upside potential in the near term, balanced by reasonable downside risk.

Financial Trend Analysis

The financial trend for Medico Remedies Ltd is currently positive. The company’s consistent quarterly profitability and improving ROCE metrics demonstrate a favourable trajectory in its financial health. The growth in PAT and PBT less other income highlights operational improvements and effective cost management. Moreover, the company’s low leverage supports sustainable growth without excessive financial risk.

However, it is important to contextualise these positive trends against the stock’s market performance. Over the past year, the stock has underperformed the BSE500 benchmark index, delivering a negative return of -30.89%. This underperformance has persisted over the last three annual periods, signalling challenges in translating operational success into shareholder returns. Investors should weigh these factors carefully when considering the stock’s medium-term outlook.

Technical Outlook

From a technical standpoint, Medico Remedies Ltd holds a mildly bearish grade as of 14 February 2026. The stock has experienced downward momentum in recent months, with a three-month decline of 12.11% and a year-to-date drop of 7.30%. The one-day and one-week changes also reflect modest negative pressure, at -1.64% and -1.55% respectively.

This technical weakness suggests caution for short-term traders, as the stock may face resistance levels and limited buying interest. However, the mildly bearish technical grade does not indicate a severe downtrend, leaving room for potential stabilisation or recovery if supported by fundamental improvements or broader market conditions.

Shareholding and Market Capitalisation

Medico Remedies Ltd is classified as a microcap company within the Pharmaceuticals & Biotechnology sector. The majority shareholding is held by promoters, which often implies stable ownership and potential alignment with long-term company interests. Investors should consider the implications of microcap status, including liquidity constraints and higher volatility, when evaluating the stock.

Summary for Investors

In summary, the 'Hold' rating for Medico Remedies Ltd reflects a balanced investment proposition. The company exhibits strong operational quality and positive financial trends, supported by efficient capital utilisation and manageable debt levels. Valuation metrics suggest the stock is fairly priced relative to earnings growth, though recent price underperformance and technical signals counsel prudence.

For investors, this rating implies that Medico Remedies Ltd may be suitable for those seeking exposure to a fundamentally sound pharmaceutical microcap with growth potential, but who are also prepared for moderate price volatility and limited near-term upside. Monitoring ongoing quarterly results and market developments will be essential to reassess the stock’s outlook over time.

Performance Metrics in Detail

Examining the stock’s recent price movements as of 14 February 2026, Medico Remedies Ltd has experienced a one-day decline of 1.64%, a one-week drop of 1.55%, and a one-month decrease of 1.20%. The three-month performance shows a more pronounced fall of 12.11%, while the six-month return is positive at 10.46%. Year-to-date, the stock has declined by 7.30%, and over the past year, it has delivered a negative return of 30.89%.

These figures highlight a mixed performance pattern, with short-term weakness and longer-term underperformance relative to broader market indices. The stock’s consistent underperformance against the BSE500 benchmark over the last three years emphasises the need for investors to carefully consider the risk-reward profile.

Financial Highlights

Medico Remedies Ltd’s financial health is underscored by several key indicators. The company’s Return on Capital Employed (ROCE) for the half-year period stands at a high 20.65%, reflecting efficient use of capital. Profit After Tax (PAT) for the latest six months is ₹5.44 crores, growing at a rate of 30.46%, while Profit Before Tax excluding other income (PBT less OI) for the latest quarter is ₹3.15 crores, with a growth rate of 52.17%. These robust growth rates demonstrate the company’s ability to expand profitability despite challenging market conditions.

Additionally, the company’s low Debt to EBITDA ratio of 0.89 times indicates a conservative capital structure, reducing financial risk and supporting sustainable operations. The fair valuation, combined with these positive financial trends, supports the current 'Hold' rating as a prudent stance for investors.

Sector and Market Context

Operating within the Pharmaceuticals & Biotechnology sector, Medico Remedies Ltd faces competitive pressures and regulatory challenges typical of the industry. The sector often demands continuous innovation and efficient cost management to maintain profitability. The company’s consistent quarterly positive results and improving ROCE suggest it is navigating these challenges effectively.

However, the microcap status and recent price underperformance relative to sector peers and benchmark indices highlight the importance of cautious investment. Investors should consider the broader market environment and sector dynamics when evaluating the stock’s potential.

Conclusion

Medico Remedies Ltd’s 'Hold' rating by MarketsMOJO, last updated on 30 December 2025, reflects a comprehensive assessment of the company’s current fundamentals, valuation, financial trends, and technical outlook as of 14 February 2026. The rating advises investors to maintain their positions without aggressive buying or selling, recognising the company’s solid operational performance alongside recent market challenges.

For those considering investment, the stock offers a balanced risk profile with potential for gradual appreciation, contingent on sustained financial improvements and favourable market conditions. Continuous monitoring of quarterly results and sector developments will be essential to inform future investment decisions.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →